{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:18:54Z","timestamp":1792034334383,"version":"4.4.0"},"reference-count":42,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>ALK and ROS1 rearrangements are essential biomarkers to be tested in advanced lung adenocarcinomas. While D5F3 Ventana assay is a companion diagnostic for anaplastic lymphoma kinase\u2013targeted therapy, immunohistochemistry is only a screening tool for detecting ROS1 rearrangement. Confirmation by cytogenetic or molecular techniques is necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To evaluate the utility of ALK and ROS1 fluorescence in situ hybridization as a complement to immunohistochemistry in routine predictive biomarker testing algorithms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>The study was ambispective, spanning 4.5 years during which lung adenocarcinoma samples were subjected to EGFR mutation testing by real-time polymerase chain reaction and ALK\/ROS1 rearrangement testing by immunohistochemistry (Ventana D5F3 assay for anaplastic lymphoma kinase protein; manual assay with D4D6 clone for Ros proto-oncogene 1 protein). Fluorescence in situ hybridization was performed in all anaplastic lymphoma kinase equivocal and Ros proto-oncogene 1 immunopositive cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Of 1874 samples included, EGFR mutations were detected in 27% (481 of 1796). Anaplastic lymphoma kinase immunohistochemistry was positive in 10% (174 of 1719) and equivocal in 3% (58 of 1719) of samples tested. ALK fluorescence in situ hybridization showed 81% (77 of 95) concordance with immunohistochemistry. Ros proto-oncogene 1 immunopositivity was noted in 13% (190 of 1425) of cases, with hybridization-confirmed rearrangements in 19.3% (26 of 135) of samples, all of which showed diffuse, strong- to moderate-intensity, cytoplasmic staining in tumor cells. Ros proto-oncogene 1 protein overexpression without rearrangement was significantly common in EGFR-mutant and ALK-rearranged adenocarcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Immunostaining is a robust method for ALK-rearrangement testing, with fluorescence in situ hybridization adding value in the rare equivocal stained case. ROS1-rearrangement testing is more cost-effective if immunohistochemistry is followed by fluorescence in situ hybridization after excluding EGFR-mutant and ALK-rearranged adenocarcinomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2023-0229-oa","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T07:02:05Z","timestamp":1701846125000},"page":"928-937","source":"Crossref","is-referenced-by-count":10,"title":["Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (\n                    <i>ALK<\/i>\n                    ) and Ros Proto-oncogene 1 (\n                    <i>ROS1<\/i>\n                    ) Gene Rearrangements in Non\u2013Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls"],"prefix":"10.5858","volume":"148","author":[{"given":"Aruna","family":"Nambirajan","sequence":"first","affiliation":[{"name":"From the Departments of Pathology (Nambirajan, Sood, Khatoon, Jain), Medical Oncology (Malik), and Pulmonary, Critical Care and Sleep Medicine (Mohan), All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridhi","family":"Sood","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Nambirajan, Sood, Khatoon, Jain), Medical Oncology (Malik), and Pulmonary, Critical Care and Sleep Medicine (Mohan), All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warisa","family":"Khatoon","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Nambirajan, Sood, Khatoon, Jain), Medical Oncology (Malik), and Pulmonary, Critical Care and Sleep Medicine (Mohan), All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Nambirajan, Sood, Khatoon, Jain), Medical Oncology (Malik), and Pulmonary, Critical Care and Sleep Medicine (Mohan), All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Mohan","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Nambirajan, Sood, Khatoon, Jain), Medical Oncology (Malik), and Pulmonary, Critical Care and Sleep Medicine (Mohan), All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Jain","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Nambirajan, Sood, Khatoon, Jain), Medical Oncology (Malik), and Pulmonary, Critical Care and Sleep Medicine (Mohan), All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b01","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN Guidelines Insights: Non\u2013Small Cell Lung Cancer, Version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b02","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jasc.2022.01.001","article-title":"Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections","volume":"11","author":"Nambirajan","year":"2022","journal-title":"J Am Soc Cytopathol"},{"key":"2024080115202933800_i1543-2165-148-8-928-b03","author":"Tsao","year":"2019","edition":"2nd ed"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b04","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.lungcan.2015.09.022","article-title":"ALK-FISH borderline cases in non-small cell lung cancer: implications for diagnostics and clinical decision making","volume":"90","author":"Von Laffert","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"2024080115202933800_i1543-2165-148-8-928-b05","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/JTO.0b013e3181fb7cd6","article-title":"Increased LAK gene copy number and amplification are frequent in non-small cell lung cancer","volume":"6","author":"Salido","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b06","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"2024080115202933800_i1543-2165-148-8-928-b07","doi-asserted-by":"crossref","first-page":"101063","DOI":"10.1016\/j.tranon.2021.101063","article-title":"The current landscape of the FDA approved companion diagnostics","volume":"14","author":"J\u00f8rgensen","year":"2021","journal-title":"Transl Oncol"},{"key":"2024080115202933800_i1543-2165-148-8-928-b08","volume-title":"Small diagnostic samples. In: WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon, France: International Agency for Research on Cancer","author":"Nicholson","year":"2021","edition":"5th ed"},{"issue":"2","key":"2024080115202933800_i1543-2165-148-8-928-b09","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/cyt.12941","article-title":"EGFR mutation testing in cytology smears of advanced non-small cell lung carcinomas: practical applications in low-resource laboratories","volume":"32","author":"Singh","year":"2021","journal-title":"Cytopathology"},{"issue":"7","key":"2024080115202933800_i1543-2165-148-8-928-b10","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.18632\/oncotarget.6921","article-title":"ROS1 copy number alterations are frequent in non-small cell lung cancer","volume":"7","author":"Clav\u00e9","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b11","doi-asserted-by":"crossref","first-page":"100561","DOI":"10.1016\/j.currproblcancer.2020.100561","article-title":"Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: multi-institutional data discussion at national conference of \u201cLung Cancer Management in Indian context\u201d","volume":"44","author":"Nakra","year":"2020","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"2024080115202933800_i1543-2165-148-8-928-b12","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1097\/JTO.0b013e318293e1ff","article-title":"Interpretation of anti-ALK immunohistochemistry results","volume":"8","author":"Takeuchi","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024080115202933800_i1543-2165-148-8-928-b13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"2024080115202933800_i1543-2165-148-8-928-b14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b15","doi-asserted-by":"crossref","first-page":"100571","DOI":"10.1016\/j.currproblcancer.2020.100571","article-title":"Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India","volume":"44","author":"Patel","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"2024080115202933800_i1543-2165-148-8-928-b16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2019.03.018","article-title":"Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer","volume":"131","author":"Lin","year":"2019","journal-title":"Lung Cancer"},{"issue":"6","key":"2024080115202933800_i1543-2165-148-8-928-b17","doi-asserted-by":"crossref","first-page":"e100866","DOI":"10.1371\/journal.pone.0100866","article-title":"Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"issue":"16","key":"2024080115202933800_i1543-2165-148-8-928-b18","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","article-title":"Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population","volume":"15","author":"Rodig","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024080115202933800_i1543-2165-148-8-928-b19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/modpathol.2013.192","article-title":"Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers","volume":"27","author":"Yoshida","year":"2014","journal-title":"Mod Pathol"},{"key":"2024080115202933800_i1543-2165-148-8-928-b20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.lungcan.2011.07.017","article-title":"ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma","volume":"75","author":"Popat","year":"2012","journal-title":"Lung Cancer"},{"issue":"8","key":"2024080115202933800_i1543-2165-148-8-928-b21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/JTO.0b013e3182936ca9","article-title":"Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone","volume":"8","author":"Savic","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024080115202933800_i1543-2165-148-8-928-b22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/ijc.IJC_470_19","article-title":"FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry \u2018Equivocal\u2019 interpretation category in the Ventana anti-ALK (D5F3) CDx assay\u2014a tertiary cancer center experience","volume":"59","author":"Singh","year":"2022","journal-title":"Indian J Cancer"},{"issue":"2","key":"2024080115202933800_i1543-2165-148-8-928-b23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncy.21510","article-title":"Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization","volume":"123","author":"Wang","year":"2015","journal-title":"Cancer Cytopathol"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/JTO.0000000000000072","article-title":"Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances","volume":"9","author":"Cabillic","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2024080115202933800_i1543-2165-148-8-928-b25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2015-0497","article-title":"Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"issue":"22","key":"2024080115202933800_i1543-2165-148-8-928-b26","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2024080115202933800_i1543-2165-148-8-928-b27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5858\/arpa.2011-0321-OA","article-title":"Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing","volume":"136","author":"Wallander","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"50","key":"2024080115202933800_i1543-2165-148-8-928-b28","doi-asserted-by":"crossref","first-page":"82943","DOI":"10.18632\/oncotarget.12705","article-title":"ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma","volume":"7","author":"Dacic","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2024080115202933800_i1543-2165-148-8-928-b29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tranon.2018.11.006","article-title":"Discordance be- tween FISH, IHC, and NGS analysis of ALK status in advanced non-small cell lung cancer (NSCLC): a brief report of 7 cases","volume":"12","author":"Scattone","year":"2019","journal-title":"Transl Oncol"},{"issue":"4","key":"2024080115202933800_i1543-2165-148-8-928-b30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2015.12.111","article-title":"ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm","volume":"11","author":"Marchetti","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/JTO.0b013e31827db604","article-title":"Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas","volume":"8","author":"Sholl","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024080115202933800_i1543-2165-148-8-928-b32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jtho.2016.08.145","article-title":"Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment","volume":"12","author":"Li","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2024080115202933800_i1543-2165-148-8-928-b33","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/JTO.0000000000000665","article-title":"Clinical implications of variant ALK FISH rearrangement patterns","volume":"10","author":"Gao","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"12","key":"2024080115202933800_i1543-2165-148-8-928-b34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11864-017-0513-x","article-title":"Anaplastic lymphoma kinase testing: IHC vs. FISH vs. NGS","volume":"18","author":"Niu","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2024080115202933800_i1543-2165-148-8-928-b35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/1759-7714.12899","article-title":"Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Thorac Cancer"},{"issue":"4","key":"2024080115202933800_i1543-2165-148-8-928-b36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/1759-7714.12191","article-title":"Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements","volume":"6","author":"Wu","year":"2015","journal-title":"Thorac Cancer"},{"key":"2024080115202933800_i1543-2165-148-8-928-b37","first-page":"19","article-title":"Incidence of ROS1-rearranged non-small-cell lung carcinoma in India and efficacy of crizotinib in lung adenocarcinoma patients. Lung","volume":"11","author":"Mehta","year":"2020","journal-title":"Cancer (Auckl)"},{"issue":"10","key":"2024080115202933800_i1543-2165-148-8-928-b38","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/ijms23105789","article-title":"A single-institute experience with C-ros oncogene 1 translocation in non-small cell lung cancers in Taiwan","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2024080115202933800_i1543-2165-148-8-928-b39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/his.13076","article-title":"Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target","volume":"70","author":"Selinger","year":"2017","journal-title":"Histopathology"},{"key":"2024080115202933800_i1543-2165-148-8-928-b40","doi-asserted-by":"crossref","first-page":"104548","DOI":"10.1016\/j.yexmp.2020.104548","article-title":"High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma","volume":"117","author":"Xu","year":"2020","journal-title":"Exp Mol Pathol"},{"key":"2024080115202933800_i1543-2165-148-8-928-b41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2021.08.003","article-title":"Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer","volume":"160","author":"Cheung","year":"2021","journal-title":"Lung Cancer"},{"issue":"2","key":"2024080115202933800_i1543-2165-148-8-928-b42","first-page":"100100","article-title":"Correlating ROS1 protein expression with ROS1 fusions, amplifications, and mutations","volume":"2","author":"Huang","year":"2020","journal-title":"JTO Clin Res Rep"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/148\/8\/928\/3414122\/i1543-2165-148-8-928.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/148\/8\/928\/3414122\/i1543-2165-148-8-928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:39:51Z","timestamp":1764790791000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/148\/8\/article-p928.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12,6]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2023-0229-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}